贝达药业：注射用MCLA-129与盐酸恩沙替尼胶囊联用治疗晚期实体瘤获得药物临床试验批准通知书

Core Viewpoint - The company, Betta Pharmaceuticals, has received approval from the National Medical Products Administration (NMPA) for its clinical trial application of MCLA-129 in combination with Enasidenib capsules [2] Group 1 - The clinical trial approval is for the injection of MCLA-129 combined with Enasidenib capsules [2] - The approval signifies a step forward in the company's research and development efforts [2]